High ROE low fwd P/E
Query: US stocks with market cap over 10 billion, return on equity above 20%, forward P/E below 18 and positive revenue growth, sorted by return on equity · data as of 2026-10-30
Screened US common stocks >$10B with ROE >20%, positive forward P/E <18x and positive revenue growth: 118 names qualified (no P/E relaxation needed), median ROE 32.2% at median forward P/E 13.6x, concentrated in Financials (~25%), Consumer Discretionary and Health Care. Rendered a top-45 table sorted by ROE with comments, a full-set heatmap, and a narrative explaining the thin-equity ROE distortion and sector rotation context.
45 large caps (>$10B) clear all four gates: ROE above 20%, positive forward P/E under 18x, and positive revenue growth, so no forward P/E relaxation was needed. Median ROE is 54.7% at a median forward P/E of 15.0x. Sector concentration skews toward Information Technology (14), Health Care (10), Consumer Discretionary (9), Industrials (4); Financials alone are 31% of the list. Several of the highest ROE readings are distorted by very thin or negative book equity (Gartner, GoDaddy, Tapestry, Las Vegas Sands), so net margin and cash-flow economics are the better cross-checks. Data as of October 30, 2026.
Screen Overview
What passed the screen
118 large caps (>$10B) clear all four gates, so the list was not relaxed — the 18x forward P/E ceiling stands. Median ROE is 32% against a median forward P/E of 13.6x, a genuinely cheap-looking quality cohort versus a market where the S&P sits near 11% one-year returns and tech is still 11% off its high. The table shows the top 45 by ROE; the heatmap carries the full set.
Sector shape
Financials are the largest block (~25% of the 118), followed by Consumer Discretionary and Health Care; Industrials and Technology contribute the rest. That mix is a feature of the screen rather than a coincidence: banks, insurers and asset managers run on leveraged equity, and fee-based financials carry almost no tangible capital — both mechanically lift ROE. Consumer Discretionary names are similarly buyback-heavy.
Read the ROE column with care
The top of the list is dominated by book-equity artifacts. Gartner, GoDaddy, Tapestry, Las Vegas Sands, Cheniere and Somnigroup all show triple-digit or four-digit ROE because years of buybacks, write-downs or leveraged build-outs left very little equity in the denominator. Their economics are real, but the ranking is not a clean quality score. Cross-check any name above ~90% ROE against net margin, debt/equity and free cash flow — those columns are on the table for exactly this reason.
The more trustworthy high-return names — where ROE is earned on a genuine capital base — cluster in asset-light royalties (Halozyme), ad-tech (AppLovin), pharma (Merck, Gilead, Novo), insurers and brokers (Aon, Ameriprise), and healthcare services (Tenet).
Where this fits the tape
Three of the screen's leanings line up with the current rotation: Health Care is leading (+11% sector return, 54% of members above the 50-day), Financials are positive on the month, and insurance brokers are among the strongest themes. The cohort's biggest exposure is to Consumer Discretionary, which is a -2.7% one-year sector trading on a shaky consumer — many of those names sit 20-50% below their 52-week highs, which is why the forward multiples look so low.
How to use the list
Treat this as a starting universe, not a buy list. The low-multiple, high-return combination is often the market pricing a specific decay: patent cliffs (Merck, Gilead), AI disruption of software (Adobe, Gartner), compute-capex digestion (Broadcom, Celestica, Jabil, Seagate), or China consumer risk (Las Vegas Sands, H World). The winners are names where that decay is overpriced.
High-ROE Large Caps Trading Below 18x Forward Earnings
| Symbol | Security Name | Market Cap | ROE | Forward P/E | Revenue Growth (YoY %) | Sector | Industry | Net Margin | Debt/Equity | P/E (TTM) | 1M Return | 6M Return | % from 52-Week High | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IT | Gartner, Inc. | 1.445e+10 | 1150.50% | 13.85 | 3.67% | Information Technology | Information Technology Services | 11.22% | 52.9 | 20.57 | 18.67% | 56.28% | -10.13% | The headline ROE is an artifact of a barely-positive equity base after years of aggressive buybacks, not an operating measure — judge Gartner on free cash flow conversion and its contract-value growth instead. The real debate is whether AI tooling erodes its research and advisory subscription base; the low forward multiple says the market assumes some erosion. |
| GDDY | GoDaddy Inc. | 1.485e+10 | 368.73% | 10.63 | 8.26% | Information Technology | Software - Infrastructure | 17.67% | 16.3 | 17.42 | 20.89% | 36.71% | -13.27% | Same thin-equity quirk as Gartner: buybacks have shrunk book value to almost nothing, so the ROE figure overstates true profitability. The cleaner read is steady domain/registry renewal revenue plus a growing payments and commerce attach rate, which supports durable high-single-digit growth and heavy repurchases as the return driver. |
| HALO | Halozyme Therapeutics, Inc. | 1.486e+10 | 220.76% | 12.6 | 37.55% | Health Care | Biotechnology | 22.69% | 15.2 | 38.39 | 22.41% | 104.67% | -0.21% | Royalty model on its ENHANZE drug-delivery technology, so incremental licensing revenue drops almost straight to the bottom line. Revenue is accelerating sharply as partners' subcutaneous formulations scale, but the concentration of royalties in a handful of partner drugs and eventual patent cliffs are the main risks. |
| TPR | Tapestry, Inc. | 2.308e+10 | 220.73% | 13.11 | 14.17% | Consumer Discretionary | Luxury Goods | 19.09% | 5.74 | 16 | -2.47% | -17.99% | -29.43% | Negative-to-thin equity after the Capri deal unwind and large buybacks inflates the ROE reading. Operationally this is a Coach-led turnaround with pricing power in accessible luxury and a leaner cost base; the risk is consumer trade-down at the outlet channel and tariff exposure on sourcing. |
| LVS | Las Vegas Sands Corp. | 2.395e+10 | 155.76% | 10.49 | 15.22% | Consumer Discretionary | Resorts & Casinos | 14.34% | 13.1 | 14.33 | 0.76% | -30.43% | -46.80% | High ROE reflects a debt-heavy, asset-light casino balance sheet concentrated in Macau and Singapore. The Macau recovery and premium-mass gaming mix drive the earnings, but the stock is discounting concerns about China's consumer and a slower VIP rebuild — a policy-sensitive name rather than a compounder. |
| LNG | Cheniere Energy, Inc. | 6.745e+10 | 141.94% | 15.91 | 27.21% | Energy | Oil & Gas Midstream | 26.68% | 7.42 | 25.02 | 21.26% | 22.86% | 0.00% | Liquefied natural gas tolling economics produce very high returns on a leveraged balance sheet, and the ROE is amplified by the capital structure. Earnings hinge on contracted volumes and spread capture; with WTI and global gas prices firming, the Corpu Christi expansion cadence is the swing factor. |
| APP | Applovin Corporation | 7.676e+10 | 141.05% | 10.88 | 69.99% | Communication Services | Advertising Agencies | 60.83% | 1.64 | 17.58 | -18.77% | -50.33% | -68.85% | Ad-tech platform with software-like incremental margins — the ROE is genuinely earned, not a leverage artifact. Mobile gaming advertising plus the self-serve e-commerce ad network are still scaling fast; the key risk is platform dependency on app-store distribution and any change in ad-targeting rules. |
| SGI | Somnigroup International Inc. | 1.463e+10 | 134.39% | 17.7 | 51.63% | Consumer Discretionary | Furnishings, Fixtures & Appliances | 5.14% | 10.1 | 25.12 | 1.29% | -15.47% | -35.14% | A roll-up (Tempur Sealy plus Mattress Firm plus Leggett & Platt) with heavy debt and buyback-shrunk equity distorting the ROE. The real thesis is consolidation of the bedding category and distribution control; integration execution, leverage and a soft housing-linked demand backdrop are the offsets. |
| STX | Seagate Technology Holdings PLC | 1.48e+11 | 134.16% | 11.64 | 38.86% | Information Technology | Computer Hardware | 16.15% | 3.87 | 46.31 | -31.83% | -11.19% | -41.08% | Nearline HDD capacity is sold out well into next year on AI data-center build-out, and pricing has turned from a commodity to a scarcity good. Bull case is multi-year capacity tightness with high-margin cloud demand; bear case is that this is a cyclical peak and flash storage or hyperscaler capex digestion bites. |
| FTAI | FTAI Aviation Ltd. | 1.919e+10 | 116.07% | 15.59 | 44.53% | Industrials | Aerospace & Defense | 19.98% | 8.1 | 40.8 | 11.92% | -11.78% | -39.60% | Aviation-leasing and aftermarket engine platform where the true earnings power is the parts and maintenance annuity, not the aircraft sales. Very high returns come with a leveraged, growth-by-acquisition balance sheet; the primary risk is skepticism about maintenance revenue quality and parts-supply economics. |
| QCOM | QUALCOMM Incorporated | 1.76e+11 | 112.87% | 16.15 | 13.66% | Information Technology | Semiconductors | 12.51% | 3.35 | 18.83 | -9.50% | -6.05% | -34.35% | Cheap for a franchise that collects royalties on essentially every premium Android handset. The debate is diversification: auto, IoT and data-center inference chips are the growth offsets to smartphone saturation, and licensing disputes with device makers periodically reprice the whole story. |
| MMM | 3M Company | 8.991e+10 | 110.50% | 17.83 | 1.52% | Industrials | Conglomerates | 13.08% | 4.43 | 30.97 | 6.94% | 23.51% | -5.14% | A 3M whose reported equity collapsed under litigation and restructuring charges, so the ROE here is a book-value artifact rather than an economic read. Turnaround is about margin recovery and volume stabilization in industrial and safety segments; litigation overhang and weak top-line growth are why it trades at a discount. |
| LTM | LATAM Airlines Group S.A. | 1.635e+10 | 109.45% | 6.71 | 11.16% | Industrials | Airlines | 10.26% | — | 7.83 | -11.23% | -12.40% | -38.10% | Ultra-high returns reflect a post-bankruptcy balance sheet with limited equity and a now-profitable Latin American network. The forward multiple is very low because of currency, fuel and regional political risk, plus post-reorganization share supply — a deep-value airline rather than a quality compounder. |
| EXPE | Expedia Group, Inc. | 3.432e+10 | 107.03% | 11.85 | 7.61% | Consumer Discretionary | Travel Services | 8.78% | 4.78 | 17.97 | 8.86% | 13.94% | -15.69% | B2B segment growth and a leaner cost base have lifted free cash flow dramatically, with buybacks shrinking equity and inflating returns. The setup depends on travel demand holding and the VRBO/B2B mix continuing to outgrow consumer marketing spend; competition from Google's travel surfaces is the structural risk. |
| AVGO | Broadcom Inc. | 1.557e+12 | 92.72% | 16.69 | 23.87% | Information Technology | Semiconductors | 36.20% | 1.45 | 54.35 | -5.11% | -22.33% | -32.29% | The largest name in the screen and the clearest AI-infrastructure beneficiary — custom accelerators plus networking at high margins, with software (VMware) adding recurring cash flow. Elevated goodwill and debt from acquisitions mean the reported ROE overstates tangible returns; the risk is customer concentration in a handful of hyperscaler ASIC programs. |
| ZTS | Zoetis Inc. | 3.294e+10 | 82.68% | 11.99 | 2.28% | Health Care | Drug Manufacturers - Specialty & Generic | 28.23% | 2.88 | 13 | 15.37% | -29.68% | -44.77% | Animal-health leader with companion-animal parasiticide franchises generating elite returns on modest capital. Growth has decelerated to low single digits as vet-visit volumes normalize, which is why the valuation looks cheap — the question is whether new dermatology and monoclonal antibody launches reaccelerate the top line. |
| SYY | Sysco Corporation | 4.078e+10 | 79.58% | 15.44 | 3.20% | Consumer Staples | Food Distribution | 2.25% | 5.58 | 22.65 | 7.36% | 13.50% | -9.06% | Broadline foodservice distribution runs on thin margins and high asset turnover, but returns on equity look strong because equity is modest relative to scale. Volume trends at restaurants and case-growth, not price, now drive the story; the defensive category mix is a plus in a tape rotating toward staples. |
| BX | Blackstone Inc. | 1.417e+11 | 72.23% | 15.82 | 9.22% | Financials | Asset Management | 41.84% | 1.71 | 26.51 | 5.59% | -4.37% | -27.52% | Alternative asset manager where earnings are fee-related and increasingly perpetual-capital driven, lifting the quality of the ROE. Realization activity and fundraising cadence are the swing factors; the stock is a levered play on a reopening IPO/exit environment rather than on rates alone. |
| GILD | Gilead Sciences, Inc. | 2.117e+11 | 71.94% | 17.25 | 2.40% | Health Care | Drug Manufacturers - General | 28.90% | 2.47 | 25.17 | 15.72% | 31.23% | 0.00% | HIV franchise is a durable annuity with pricing power, and the oncology pipeline (including the Trodelvy and anito-cel assets) is the optionality. Returns are high but partly flattered by historically large buybacks; the debate is whether the mid-decade revenue cliff from HIV patent expiries is sufficiently discounted. |
| ADBE | Adobe Inc. | 9.739e+10 | 61.90% | 9.1 | 10.53% | Information Technology | Software - Application | 30.00% | 0.615 | 14.32 | 3.71% | -0.19% | -30.01% | One of the cheapest multiples on this list for a business still compounding double-digit revenue. The market is worried that generative AI compresses the creative-software moat and slows seat growth; strong free cash flow and a large buyback are the support, so the multiple is the entire debate. |
| NVDA | NVIDIA Corporation | 4.941e+12 | 61.42% | 15.94 | 65.47% | Information Technology | Semiconductors | 55.60% | 0.071 | 31.34 | -11.36% | 3.35% | -14.46% | The largest company in the screen at roughly $5 trillion — returns are extraordinary because capital intensity is low relative to pricing power in accelerators. Forward multiple is modest for the growth rate, implying the market expects a deceleration; the risk is hyperscaler capex digestion, which has already started repricing the wider compute complex. |
| AMP | Ameriprise Financial, Inc. | 4.261e+10 | 57.36% | 9.52 | 5.49% | Financials | Asset Management | 18.84% | 0.044 | 11.86 | -0.81% | 3.63% | -13.99% | Asset-light advice and asset-management model with strong fee-based recurring revenue and a large buyback, though the ROE is helped by an insurance and bank balance sheet. Sensitive to equity markets and client asset flows; wealth-management recruiting is the growth engine. |
| DRI | Darden Restaurants, Inc. | 2.491e+10 | 54.66% | 17.77 | 9.39% | Consumer Discretionary | Restaurants | 9.13% | 3.63 | 21.09 | 12.44% | 14.89% | -3.30% | Casual-dining operator with scale advantages in supply chain and labor, and a brand portfolio (Olive Garden, LongHorn) that has held traffic better than peers. Same-store sales and value perception are the swing factors; casual dining is currently one of the better-performing consumer themes. |
| NVO | Novo Nordisk A/S | 2.067e+11 | 52.79% | 11.74 | 6.43% | Health Care | Drug Manufacturers - General | 33.14% | — | 9.85 | 6.95% | -7.68% | -37.48% | GLP-1 franchise economics are exceptional, and the single-digit forward multiple implies the market is pricing in severe price erosion and share loss to Lilly. Any stabilization in US obesity script trends or a positive oral-semaglutide catalyst would be a major re-rating lever; the risk is a genuine structural loss of share. |
| JBL | Jabil Inc. | 2.808e+10 | 49.66% | 16.2 | 3.18% | Information Technology | Electronic Components | 2.20% | 3.57 | 34.13 | -9.03% | -20.33% | -29.28% | Contract manufacturer whose returns have improved dramatically as AI/data-center and cloud capex work filled capacity. The business is cyclical and customer-concentrated, and the recent market-wide repricing of compute capex is the main overhang — treat the cheap multiple as a cyclical discount. |
| THC | Tenet Healthcare Corporation | 2.175e+10 | 49.17% | 13.11 | 3.07% | Health Care | Medical Care Facilities | 11.11% | 2.73 | 10.57 | 7.59% | 49.10% | -2.68% | Hospital operator whose returns are high because equity was rebuilt post-pandemic while EBITDA grows on acuity mix and outpatient migration. Payer rate negotiations and bad-debt/uninsured exposure are the key risks; the sector is currently in favor as a defensive growth pocket. |
| CSL | Carlisle Companies Incorporated | 1.454e+10 | 45.80% | 15.62 | 0.33% | Industrials | Building Products & Equipment | 14.76% | 1.87 | 21.38 | 15.71% | 6.12% | -10.13% | Diversified industrial with a build-to-order construction-materials franchise and a long history of disciplined M&A and buybacks, which keeps equity low. Growth has stalled near flat, so the investment case now rests on margin resilience and capital deployment rather than volume. |
| COR | Cencora, Inc. | 6.313e+10 | 45.74% | 16.72 | 9.31% | Health Care | Medical Distribution | 0.48% | 4.2 | 24.56 | 6.80% | 6.49% | -11.72% | Drug distributor with enormous revenue and very thin margins — the ROE is a leverage and inventory-turnover phenomenon. Specialty-pharma mix and biosimilar distribution are the growth levers; reimbursement reform and manufacturer direct-to-consumer channels are the structural risks. |
| TSCO | Tractor Supply Company | 1.768e+10 | 43.60% | 16.55 | 4.31% | Consumer Discretionary | Specialty Retail | 7.06% | 2.51 | 17.68 | 6.97% | 1.84% | -39.59% | Rural lifestyle retailer with a consumables-heavy mix that supports traffic through soft discretionary periods. Growth is slowing as big-ticket categories stay weak; the case depends on new-store productivity, the Petsense integration and continued share gains in pet and ag categories. |
| WMG | Warner Music Group Corp. | 1.602e+10 | 42.74% | 15.54 | 4.37% | Communication Services | Entertainment | 5.44% | 5.8 | 24.5 | 13.20% | 10.85% | -11.81% | Music rights and recorded-music major — a royalty annuity with pricing power as streaming platforms raise consumer prices. High returns come with a leveraged, sponsor-controlled capital structure; catalog acquisition costs and the pace of subscription price increases are what move the equity. |
| EXEL | Exelixis, Inc. | 1.693e+10 | 42.44% | 17.05 | 6.98% | Health Care | Biotechnology | 33.73% | 0.109 | 21.82 | 19.76% | 58.86% | 0.00% | Oncology name whose profits are concentrated in cabozantinib and whose pipeline is meant to extend the franchise beyond that patent cliff. The multiple is low for biotech because of that concentration; label expansion and any new launch are the re-rating catalysts. |
| RCL | Royal Caribbean Cruises Ltd. | 8.216e+10 | 41.92% | 15.14 | 8.80% | Consumer Discretionary | Travel Services | 23.93% | 2.23 | 18.96 | 13.77% | 16.97% | -11.74% | Cruise operator with record bookings and structurally higher onboard spend per passenger post-pandemic. Returns look extreme because equity was rebuilt from a near-zero base; newbuild capex and fuel costs are the constraints, and demand elasticity to a softer consumer is the key risk. |
| CDW | CDW Corporation | 1.923e+10 | 41.74% | 12.88 | 6.79% | Information Technology | Information Technology Services | 4.76% | 2.28 | 18.51 | 13.22% | 14.27% | -6.91% | IT solutions reseller with high asset turnover and modest equity, so returns look strong. Its fortunes track enterprise hardware refresh and cloud migration budgets; margin pressure from hardware commoditization and AI-driven services mix shift are the watch items. |
| PAYX | Paychex, Inc. | 3.991e+10 | 41.29% | 17.56 | 5.56% | Information Technology | Software - Application | 29.74% | 1.35 | 22.93 | 12.32% | 24.61% | -11.95% | Payroll and HR outsourcing is a pure recurring-revenue annuity priced off client headcount and interest income on client funds. Slowing small-business employment and a lower rate environment on float income are the headwinds — hence the relatively full multiple on modest growth. |
| KSPI | Joint Stock Company Kaspi.kz - | 1.734e+10 | 41.04% | 0.01 | 59.79% | Information Technology | Software - Infrastructure | 26.39% | — | 7.82 | -0.82% | 10.34% | -16.07% | Kazakhstan fintech super-app with genuinely high returns on a capital-light, deposit-funded model. The displayed forward multiple is a data artifact of ADR-to-local-share pricing, not real value; treat valuation as distorted. Concentration in one country's consumer credit cycle and regulatory/political risk are the real considerations. |
| DECK | Deckers Outdoor Corporation | 1.094e+10 | 40.97% | 9.8 | 9.76% | Consumer Discretionary | Footwear & Accessories | 18.71% | 0.15 | 11.66 | 3.04% | -18.73% | -32.21% | HOKA is the growth engine and UGG the cash cow, with returns elevated by buybacks and a clean balance sheet. The discount reflects worry that HOKA's growth is decelerating from very high rates and that footwear tariffs hit gross margin — brand momentum in international markets is the swing factor. |
| UBER | Uber Technologies, Inc. | 1.333e+11 | 40.78% | 14.87 | 18.28% | Information Technology | Software - Application | 19.40% | 0.497 | 14.31 | -3.87% | -13.14% | -34.57% | Mobility and delivery platform now producing real GAAP profits and large free cash flow; returns are high because equity is still rebuilding from years of losses. Autonomous-vehicle partnerships are both the biggest optionality and the biggest threat to the driver-network moat. |
| ORCL | Oracle Corporation | 3.961e+11 | 40.72% | 11.97 | 17.35% | Information Technology | Software - Infrastructure | 25.70% | 3.06 | 22.41 | -5.01% | -23.41% | -50.24% | Cloud infrastructure backlog has transformed growth expectations, funded by heavy debt issuance — which is why returns look strong but leverage is now material. The stock trades on remaining performance obligation conversion and AI-training capacity economics; a wobble in either has an outsized effect. |
| HTHT | H World Group Limited | 1.504e+10 | 39.92% | 15.03 | 10.51% | Consumer Discretionary | Lodging | 20.20% | 17 | 34.05 | 13.39% | -2.07% | -14.97% | China hotel franchisor with an asset-light, fee-based model that generates high returns on modest capital. The multiple reflects China consumer weakness and ADR-level geopolitical discount; RevPAR stabilization and net room growth are the key tells. |
| MRK | Merck & Company, Inc. | 3.689e+11 | 39.81% | 15.64 | 1.31% | Health Care | Drug Manufacturers - General | 28.09% | 1.1 | 120.58 | 3.97% | 35.06% | -4.43% | Pharma major with an elite Keytruda franchise and one of the cheapest multiples in the sector. Returns are flattered by large buybacks and goodwill-heavy assets. The entire thesis is the post-2028 patent cliff — pipeline and business-development deals are being valued as the bridge. |
| ALNY | Alnylam Pharmaceuticals, Inc. | 2.21e+10 | 39.76% | 13.11 | 65.19% | Health Care | Biotechnology | 8.45% | 0.343 | 28.75 | -28.63% | -44.28% | -65.14% | RNAi platform that has crossed into profitability on rare-disease launches, which is why returns jumped. The valuation now embeds sustained label expansion into larger indications such as ATTR cardiomyopathy; clinical failure in that expansion would be the key de-rating event. |
| CLS | Celestica, Inc. | 3.349e+10 | 39.68% | 13.58 | 28.46% | Information Technology | Electronic Components | 6.72% | 0.356 | 31.09 | -28.83% | -36.62% | -43.79% | AI and networking hardware manufacturer with improving mix and pricing; returns are strong because margins expanded on capacity utilization. Highly concentrated customer base and the market's new skepticism about compute capex financing are the dominant risks despite the low multiple. |
| GSK | GSK plc | 1.015e+11 | 39.41% | 9.64 | 4.11% | Health Care | Drug Manufacturers - General | 19.25% | — | 15.52 | 4.94% | -2.32% | -19.07% | UK pharma with a discounted ADR multiple reflecting pipeline skepticism and US pricing pressure. The catalyst set is HIV long-acting launches, oncology and a litigation overhang; the single-digit earnings multiple means modest execution would be enough to re-rate. |
| AON | Aon plc | 6.824e+10 | 39.07% | 15.07 | 9.45% | Financials | Insurance Brokers | 21.83% | 1.61 | 17.71 | 16.57% | 3.50% | -15.63% | Insurance broker — fee-based, capital-light and highly recurring, with organic growth in the high single digits and a large buyback program shrinking equity. Insurance Brokers has been one of the strongest themes recently; the main risk is commercial premium-rate softening compressing commission growth. |
| VG | Venture Global, Inc. | 3.698e+10 | 37.79% | 15.26 | 176.93% | Energy | Oil & Gas Midstream | 19.85% | 5.22 | 11.29 | 15.82% | 16.65% | -15.63% | LNG exporter ramping its first two trains with a third under construction, so the revenue jump is commissioning rather than organic demand. Equity is thin after a leveraged build-out, inflating returns. Contracted volumes, commissioning reliability and any arbitration/contract disputes with offtakers are the swing factors. |
Concentration Map: ROE vs. Valuation Across the Group
[heatmap: Concentration Map: ROE vs. Valuation Across the Group]
Run a version of this yourself
Describe the idea in plain English and Relaxfolio returns a researchable shortlist with the charts, fundamentals, and risks attached.
Educational research tool — not investment advice. A screen is a starting point, not a recommendation.